Single-photon emission computed tomography

The nuclear medicine market is projected to grow at a CAGR of 5.9%

Retrieved on: 
星期三, 六月 20, 2018
Medicine, Medicinal radiochemistry, Health, Chemistry, Medical physics, Radiopharmaceuticals, Radiobiology, Radiochemistry, Nuclear medicine, Single-photon emission computed tomography

The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018.

Key Points: 
  • The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018.
  • However, the short half-life of radiopharmaceuticals, hospital budget cuts, and high equipment prices are likely to restrain market growth.
  • Based on type, the nuclear medicine market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals.The diagnostic radiopharmaceuticals have been segmented into SPECT and PET radiopharmaceuticals.
  • The nuclear medicine market is divided into four major regions North America, Europe, Asia Pacific, and the Rest of the World.North America accounted for the largest share of the nuclear medicine market.

Global Nuclear Medicine/Radiopharmaceuticals Market 2018-2023: Major Players are Cardinal Health, GE Healthcare, and Curium

Retrieved on: 
星期二, 六月 19, 2018
Medicine, Radiobiology, Medicinal radiochemistry, Medical physics, Neuroimaging, Nuclear medicine, Radiology, Clinical medicine, Single-photon emission computed tomography, Nuclear medicine physician

By type, the global nuclear medicine market is segmented diagnostic and therapeutic nuclear medicine.

Key Points: 
  • By type, the global nuclear medicine market is segmented diagnostic and therapeutic nuclear medicine.
  • Based on applications, the nuclear medicine market is segmented into diagnostic and therapeutic applications.
  • The SPECT application segment accounted for the largest share of the diagnostic nuclear medicine market by applications owing to the rising demand for cardiac imaging.
  • Based on procedural volume, the nuclear medicine market is segmented into volumes for diagnostic and therapeutic procedures.

Nuclear Medicine/Radiopharmaceuticals Market Worth 5.26 Billion USD by 2023

Retrieved on: 
星期四, 六月 14, 2018
Medicine, Medicinal radiochemistry, Chemistry, Clinical medicine, Medical physics, Radiobiology, Radiopharmaceuticals, Radiochemistry, Nuclear medicine, Technetium-99m, Single-photon emission computed tomography, Brachytherapy

According to a new market research report "Nuclear Medicine/Radiopharmaceuticals Marketby Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023", published by MarketsandMarkets, the global market is expected to grow at a CAGR of 5.9% during the forecast period, to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018.

Key Points: 
  • According to a new market research report "Nuclear Medicine/Radiopharmaceuticals Marketby Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023", published by MarketsandMarkets, the global market is expected to grow at a CAGR of 5.9% during the forecast period, to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018.
  • Based on type, the Nuclear Medicine Market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals.
  • In 2017, the Tc-99m segment accounted for the largest share of the nuclear medicine SPECT Radiopharmaceuticals Market.
  • The oncology segment is projected to account for the largest share of the PET Nuclear Medicine Market during the forecast period.